2. Vitamin D Related/Nuclear Receptor
  3. VD/VDR
  4. MeTC7

MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC50 value of 2.9 μM. MeTC7 shows good antitumor effects.

For research use only. We do not sell to patients.

CAS No. : 1817841-22-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

MeTC7 Related Antibodies

Top Publications Citing Use of Products

    MeTC7 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jun 12:e2507657.  [Abstract]

    Schematic representation of VDR blockade using MeTC7. Mice were administered 50 mg/kg of MeTC7 intraperitoneally, and 12 h later, mRNA LNPs were administered intravenously.

    MeTC7 purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jun 12:e2507657.  [Abstract]

    To investigate the role of VDR, mice were pre-administering with VDR antagonist MeTC7 or PBS (control) 12 h before LNP administration. Representative IVIS images at 24 h post-injection of LNPs (0.5 mg/kg) in C57BL/6 mice (n = 4 biologically independent mice). Organs are arranged left to right as: heart, lung, spleen, pancreas, liver, kidneys and intestines.

    MeTC7 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Mar 25;26(7):2985.

    Western blot detection of p-P65Ser311, P65, TNFα, MCP-1, KIM1, and NGAL expression in cells after administration of MeTC7 and/or DKS26-treated mRETCs; n = 3. MeTC7: 200 nM, DKS26: 100 μg/mL.

    MeTC7 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Mar 25;26(7):2985.

    Effects of MeTC7 and DKS26 on the nuclear translocation of p-P65Ser311 (red) observed by laser confocal microscopy.

    MeTC7 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Mar 25;26(7):2985.

    Western blot analysis of p-IKKβ, IKKβ, p-IKBα, and IKBα expression in cells treated with DKS26 and/or MeTC7; n = 3. MeTC7: 200 nM, DKS26: 100 μg/mL.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC50 value of 2.9 μM. MeTC7 shows good antitumor effects[1].

    IC50 & Target

    IC50: 2.9 μM (VDR)[1].
    In Vitro

    MeTC7 (compound 5) shows potent VDR inhibition activity with an IC50 value of 2.9 μM[1].
    MeTC7 disrupts the VDR-Ligand-binding domain in Silico[1].
    MeTC7 (250 nM; 18 h) suppresses RXRα and Importin-4 expressions in the ovarian cancer cell-line[1].
    MeTC7 (250 nM; 18 h) inhibits the viability of ovarian cancer cells and induces PARP1 cleavage[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    MeTC7 Related Antibodies

    Western Blot Analysis[1]

    Cell Line: 2008 cells
    Concentration: 250 nM
    Incubation Time: 18, 12 h
    Result: Reduced the expression of RXR-α, Importin-4 and increased cleaved PARP1 expression in 2008 cells.

    Cell Viability Assay[1]

    Cell Line: SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines
    Concentration: 0, 0.25, 0.5, 0.75, 1.0, 1.25 μM
    Incubation Time: 24 h
    Result: Reduced the viability of SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines.
    In Vivo

    MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Mice[1]
    Dosage: 10 mg/kg
    Administration: IP
    Result: Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells.
    Inhibited the growth of neuroblastoma cells and Xenografts.
    Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma.
    Molecular Weight

    618.65

    Formula

    C32H48BrN3O4
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C1N2C34[C@@](CC[C@]5([C@@]4([H])CC[C@]5([H])[C@H](C)CCCC(C)C)C)([H])[C@@]6(C(C=C3)(C[C@H](CC6)OC(CBr)=O)N2C(N1C)=O)C
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 16.67 mg/mL (26.95 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.6164 mL 8.0821 mL 16.1642 mL
    5 mM 0.3233 mL 1.6164 mL 3.2328 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 1.67 mg/mL (2.70 mM); Clear solution

      This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 98.50%

    SDS (251 KB)

    COA (253 KB) HNMR (148 KB) LCMS (94 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.6164 mL 8.0821 mL 16.1642 mL 40.4106 mL
    5 mM 0.3233 mL 1.6164 mL 3.2328 mL 8.0821 mL
    10 mM 0.1616 mL 0.8082 mL 1.6164 mL 4.0411 mL
    15 mM 0.1078 mL 0.5388 mL 1.0776 mL 2.6940 mL
    20 mM 0.0808 mL 0.4041 mL 0.8082 mL 2.0205 mL
    25 mM 0.0647 mL 0.3233 mL 0.6466 mL 1.6164 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    MeTC7 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    MeTC71817841-22-7MeTC 7MeTC-7VD/VDRVitamin DVitamin D receptorVitamin-D receptor (VDR)inhibitionantitumorcancerInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    MeTC7
    Cat. No.:
    HY-147337
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.